Strategic partnerships Corgenix is actively engaged in collaborations with biotech and pharma entities (examples include AroCell and Eli Lilly) and operates as a CDMO with end-to-end IVD process support. This positions potential for expanded CDMO services, including development, regulatory, manufacturing, and commercialization support for new client programs.

Regulatory readiness The company maintains CAP/CLIA accreditation, ISO-13485:2016, FDA registration, and GMP compliance, highlighting a strong quality framework. This can ease risk for prospective clients seeking reliable clinical testing, QA, and compliant manufacturing partnerships.

Clinical trial capability With expertise in clinical studies, trial management, physician-ordered patient testing, and warehousing/distribution, Corgenix can offer end-to-end trial logistics and biomarker testing services to biotech and pharma clients pursuing accelerated development timelines.

Ebola and infectious disease focus Recent recognition for rapid diagnostic test development for Ebola and other infectious disease applications indicates capability in rapid turnaround diagnostics. This creates sales opportunities in infectious disease screening, emergency response programs, and frontier diagnostic platforms.

Mid-market scale opportunity Operating with 11-50 employees and reported revenue in the mid-range, Corgenix sits between large CROs and smaller labs. This positioning is attractive to mid-sized biotech firms and startups seeking flexible, personalized, and cost-efficient testing and development partnerships.